Abstract

Proper diagnostic distinction of bone marrow failure syndromes can often be challenging. In particular, for older patients with idiopathic aplastic anemia (AA), differential diagnosis includes myelodysplastic syndrome (MDS), which can atypically present in a hypocellular form. In addition to blasts and overt dysplasia, the presence of chromosomal abnormalities and a spectrum of somatic mutations may be revealing. Both clonal cytogenetic aberrations and somatic mutations most typically correspond to a clonal myelodysplasia, but clonal somatic mutations have also recently been found in AA. True driver myeloid mutations are uncommon in AA. Marrow hypocellularity in AA and occasionally in MDS patients points toward a similar immune mechanism responsible for deficient blood cell production and indicates that cytopenias in early hypocellular MDS might be treated with immunosuppressive modalities. Primary hypocellular MDS has to be distinguished from post-AA secondary MDS, most commonly associated with del7/7q. Post-AA MDS evolves at the rate of about 10% in 10 years, but recent observations suggest that widespread use of eltrombopag may influence the risk of progression to MDS. This complication likely represents a clonal escape, with founder hits occurring early on in the course of AA. A similar mechanism operates in the evolution of paroxysmal nocturnal hemoglobinuria (PNH) in AA patients, but PNH clones are rarely encountered in primary MDS.

References

References
1.
Wilson
DB
,
Link
DC
,
Mason
PJ
,
Bessler
M
.
Inherited bone marrow failure syndromes in adolescents and young adults
.
Ann Med
.
2014
;
46
(
6
):
353
-
363
.
2.
Dokal
I
,
Vulliamy
T
.
Inherited bone marrow failure syndromes
.
Haematologica
.
2010
;
95
(
8
):
1236
-
1240
.
3.
Chirnomas
SD
,
Kupfer
GM
.
The inherited bone marrow failure syndromes
.
Pediatr Clin North Am
.
2013
;
60
(
6
):
1291
-
1310
.
4.
Jaiswal
S
,
Fontanillas
P
,
Flannick
J
, et al
.
Age-related clonal hematopoiesis associated with adverse outcomes
.
N Engl J Med
.
2014
;
371
(
26
):
2488
-
2498
.
5.
Bono
E
,
McLornan
D
,
Travaglino
E
, et al
.
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome [published online ahead of print 2 April 2019]
.
Leukemia
.
doi:10.1038/s41375-019-0457-1
.
6.
Tong
WG
,
Quintás-Cardama
A
,
Kadia
T
, et al
.
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system
.
Cancer
.
2012
;
118
(
18
):
4462
-
4470
.
7.
Maschek
H
,
Kaloutsi
V
,
Rodriguez-Kaiser
M
, et al
.
Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis
.
Ann Hematol
.
1993
;
66
(
3
):
117
-
122
.
8.
Young
NS
,
Scheinberg
P
,
Calado
RT
.
Aplastic anemia
.
Curr Opin Hematol
.
2008
;
15
(
3
):
162
-
168
.
9.
Young
NS
.
Aplastic anemia
.
N Engl J Med
.
2018
;
379
(
17
):
1643
-
1656
.
10.
Tichelli
A
,
Gratwohl
A
,
Nissen
C
,
Signer
E
,
Stebler Gysi
C
,
Speck
B
.
Morphology in patients with severe aplastic anemia treated with antilymphocyte globulin
.
Blood
.
1992
;
80
(
2
):
337
-
345
.
11.
Young
NS
,
Maciejewski
JP
.
Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes “Why? Why? Why?”
.
J Clin Invest
.
2000
;
106
(
5
):
637
-
641
.
12.
Maciejewski
JP
,
Risitano
A
,
Sloand
EM
,
Nunez
O
,
Young
NS
.
Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia
.
Blood
.
2002
;
99
(
9
):
3129
-
3135
.
13.
Afable
MG
II
,
Tiu
RV
,
Maciejewski
JP
.
Clonal evolution in aplastic anemia
.
Hematology Am Soc Hematol Educ Program
.
2011
;
2011
:
90
-
95
.
14.
Afable
MG
II
,
Wlodarski
M
,
Makishima
H
, et al
.
SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes
.
Blood
.
2011
;
117
(
25
):
6876
-
6884
.
15.
Gondek
LP
,
Tiu
R
,
O’Keefe
CL
,
Sekeres
MA
,
Theil
KS
,
Maciejewski
JP
.
Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML
.
Blood
.
2008
;
111
(
3
):
1534
-
1542
.
16.
Arenillas
L
,
Calvo
X
,
Luño
E
, et al
.
Considering bone marrow blasts from nonerythroid cellularity improves the prognostic evaluation of myelodysplastic syndromes
.
J Clin Oncol
.
2016
;
34
(
27
):
3284
-
3292
.
17.
Nazha
A
,
Seastone
D
,
Radivoyevitch
T
, et al
.
Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes
.
Haematologica
.
2015
;
100
(
11
):
e434
-
e437
.
18.
Negoro
E
,
Nagata
Y
,
Clemente
MJ
, et al
.
Origins of myelodysplastic syndromes after aplastic anemia
.
Blood
.
2017
;
130
(
17
):
1953
-
1957
.
19.
Yoshizato
T
,
Dumitriu
B
,
Hosokawa
K
, et al
.
Somatic mutations and clonal hematopoiesis in aplastic anemia
.
N Engl J Med
.
2015
;
373
(
1
):
35
-
47
.
20.
Ogawa
S
.
Clonal hematopoiesis in acquired aplastic anemia
.
Blood
.
2016
;
128
(
3
):
337
-
347
.
21.
Biesma
DH
,
van den Tweel
JG
,
Verdonck
LF
.
Immunosuppressive therapy for hypoplastic myelodysplastic syndrome
.
Cancer
.
1997
;
79
(
8
):
1548
-
1551
.
22.
Calado
RT
.
Immunologic aspects of hypoplastic myelodysplastic syndrome
.
Semin Oncol
.
2011
;
38
(
5
):
667
-
672
.
23.
Stahl
M
,
DeVeaux
M
,
de Witte
T
, et al
.
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
.
Blood Adv
.
2018
;
2
(
14
):
1765
-
1772
.
24.
Greenberg
PL
,
Tuechler
H
,
Schanz
J
, et al
.
Revised international prognostic scoring system for myelodysplastic syndromes
.
Blood
.
2012
;
120
(
12
):
2454
-
2465
.
25.
Winkler
T
,
Fan
X
,
Cooper
J
, et al
.
Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag
.
Blood
.
2019
;
133
:
2575
-
2585
26.
da Silva-Coelho
P
,
Kroeze
LI
,
Yoshida
K
, et al
.
Clonal evolution in myelodysplastic syndromes
.
Nat Commun
.
2017
;
8
(
1
):
15099
.
27.
Ogawa
S
.
MDS-related mutations in aplastic anemia
.
Blood
.
2014
;
124
(
17
):
2619
-
2620
.
28.
Sperling
AS
,
Gibson
CJ
,
Ebert
BL
.
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
.
Nat Rev Cancer
.
2017
;
17
(
1
):
5
-
19
.
29.
Jerez
A
,
Sugimoto
Y
,
Makishima
H
, et al
.
Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis
.
Blood
.
2012
;
119
(
25
):
6109
-
6117
.
30.
Wlodarski
MW
,
Collin
M
,
Horwitz
MS
.
GATA2 deficiency and related myeloid neoplasms
.
Semin Hematol
.
2017
;
54
(
2
):
81
-
86
.
31.
Nagata
Y
,
Narumi
S
,
Guan
Y
, et al
.
Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes
.
Blood
.
2018
;
132
(
21
):
2309
-
2313
.
32.
Shallis
RM
,
Chokr
N
,
Stahl
M
,
Pine
AB
,
Zeidan
AM
.
Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place
.
Expert Rev Hematol
.
2018
;
11
(
9
):
715
-
726
.
33.
Saunthararajah
Y
,
Molldrem
JL
,
Rivera
M
, et al
.
Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features
.
Br J Haematol
.
2001
;
112
(
1
):
195
-
200
.
You do not currently have access to this content.